• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Micromet, Inc. - Product Pipeline Review - H2 2011 Product Image

Micromet, Inc. - Product Pipeline Review - H2 2011

  • ID: 1925671
  • September 2011
  • 80 pages
  • Global Markets Direct

Micromet, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Micromet, Inc. – Product Pipeline Review – H2 2011” provides data on the Micromet, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Micromet, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Micromet, Inc. and industry–specific third party sources, put together by Global Markets Direct’s team.

Scope

- Micromet, Inc. - Brief Micromet, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Micromet, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Micromet, Inc. Snapshot
Micromet, Inc. Overview
Key Information
Key Facts
Micromet, Inc. – Research and Development Overview
Key Therapeutic Areas
Micromet, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Micromet, Inc. – Pipeline Products Glance
Micromet, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Micromet, Inc. – Drug Profiles
BiTE For Solid Tumors
Product Description
Mechanism of Action
R&D Progress
Solid Tumor BiTE
Product Description
Mechanism of Action
R&D Progress
Micromet, Inc. - Pipeline Products By Target
Micromet, Inc. – Pipeline Products by Molecule Type
Micromet, Inc. – Recent Pipeline Updates
Micromet, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Canvaxin
Micromet, Inc. – Company Statement
Micromet, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Nov 29, 2007: Micromet And MedImmune Presents Clinical Data For Anti-CD19 BiTE Antibody At American Society Of Hematology Annual Meeting
Oct 29, 2009: Micromet And Sanofi-aventis Signs Global Collaboration And License Agreement For New Solid Tumor BiTE Antibody
Jan 28, 2009: New Data Published in Immunobiology Describe Mode of Action of BiTE Antibody MT110.
Apr 27, 2005: Micromet Launches Phase I Trial Combining Its Antibody MT201 With Docetaxel For The Treatment Of Breast Cancer
Feb 25, 2004: Micromet And Boehringer Ingelheim Collaborate On Manufacturing Of Micromet's Anti-Cancer Antibody MT201
Apr 24, 2009: Micromet Presents Data At AACR Meeting Showing Elimination Of Colorectal Cancer Stem Cells By BiTE Antibody MT110
Nov 23, 2004: Micromet Receives Investigational New Drug Designation (IND) For MT201
May 23, 2011: Micromet To Report Blinatumomab Data At Upcoming Medical Conferences In June 2011
Apr 23, 2008: Micromet Enrolls First Patient In A Phase I Clinical Trial with MT110, The First BiTE Antibody For Treatment Of Solid Tumors.
Mar 23, 2009: Micromet Starts A New Phase 2 Trial For Adecatumumab In Patients With Colorectal Cancer
May 22, 2008: Micromet To Present Clinical Update For BiTE Antibody MT103/MEDI-538 At The International Conference On Malignant Lymphomas
Apr 22, 2009: Micromet Presents Preclinical Data Showing Activity Of Erbitux And Vectibix Based BiTE Antibodies Against KRAS- And BRAF-Mutated Human Colorectal Cancer Cells
Sep 21, 2009: Micromet Reports Interim Data From Phase I Study Of BiTE Antibody MT110 For The Treatment Of Solid Tumors.
Aug 21, 2006: MedImmune Files Investigational New Drug Application For MT103
May 21, 2010: Micromet To Provide Update On BiTE Antibody Development Programs At Upcoming Medical Conferences
Dec 20, 2004: Serono And CancerVax Corporation Enters Into Agreement For The Development And Commercializatian Of Canvaxin For Melanoma
Sep 20, 2010: Micromet Initiates European Pivotal Trial Of Blinatumomab In Adult With Acute Lymphoblastic Leukemia
Sep 20, 2010: Micromet Initiates Phase II Trial Of Blinatumomab In Adults With Relapsed/Refractory Acute Lymphoblastic Leukemia
Oct 18, 2007: Micromet Receives Regulatory Approval To Conduct Phase II Clinical Trial For MT103/MEDI-538
Sep 18, 2008: Micromet, Inc and Serono Reports The Phase II Trials Data Of MT201
Apr 18, 2007: Micromet And MedImmune Present Data From Preclinical Study Of New BiTE Molecule Targeting CEA
May 17, 2011: Data Published In Journal Of Clinical Oncology Highlights Significant Activity Of Micromet's Blinatumomab In Patients With Acute Lymphoblastic Leukemia
Sep 15, 2008: Micromet Presents Interim Data Of Adecatumumab In Combination With Chemotherapy
Jun 14, 2010: Micromet Announces Updated Results From Phase II Trial Of Blinatumomab In Patients With Acute Lymphoblastic Leukemia
Jun 14, 2010: Micromet's Blinatumomab Induces Durable Remissions In Patients With Relapsed Non-Hodgkin's Lymphoma
Nov 13, 2008: Micromet Presents Interim Data Of Blinatumomab At American Society of Hematolgy Annual Meeting
Jun 12, 2008: Micromet And MedImmune Commence Phase II Trial Of BiTE Antibody Blinatumomab In Patients With Acute Lymphoblastic Leukemia
Jan 12, 2011: Medimmune And Micromet Initiate Phase I Trial Of MT111 In Advanced Gastrointestinal Cancers
Oct 11, 2010: Micromet Announces FDA Acceptance Of IND For BiTE Antibody MT111/MEDI-565
Feb 11, 2004: Micromet's Initiates Phase II Trial For MT201 In Prostate Cancer
Dec 10, 2007: Micromet And MedImmune Presents Clinical Data For MT103 At The American Society Of Hematology Annual Meeting
Jun 10, 2011: Study Demonstrates Micromet's Blinatumomab Produces High Single-Agent Activity In Patients With Relapsed Acute Lymphoblastic Leukemia
Feb 10, 2010: Micromet Highlights Clinical Plans And Regulatory Strategy For Blinatumomab
Dec 09, 2008: Micromet Presents Updated Data On Phase I Trial Study Of Blinatumomab In Patients With Advanced Non-Hodgkin's Lymphoma
Nov 09, 2010: Micromet To Provide Update On BiTE Antibody R&D Programs At 2010 American Society Of Hematology Annual Meeting
Jun 09, 2003: MedImmune Signs An Agreement With Micromet To Co-Develop MT103 For The Treatment Of B-Cell Tumors
Mar 09, 2004: Micromet Initiates Phase II Trial In Breast Cancer For MT201
Dec 08, 2009: Micromet Announces Phase II Study Results Of Blinatumomab For The Treatment Of Acute Lymphoblastic Leukemia
Nov 08, 2010: Micromet To Advance MT112/BAY 2010112 Into IND-Enabling Preclinical Development Activities In Collaboration With Bayer Schering Pharma
Jun 08, 2009: Micromet Presents Phase II Clinical Data Of Blinatumomab (MT103) At The 14th Congress Of European Hematology Association
Apr 08, 2009: Pre-Clinical Data on CEA-specific BiTE Antibody Published In Journal Of Immunotherapy Demonstrate Potent Control Of Tumor Growth
Dec 07, 2010: Micromet's Blinatumomab Produces High Objective Response Rate In Spectrum Of Relapsed Non-Hodgkin's Lymphoma Patients
Dec 07, 2004: Serono And Micromet To Collaborate In Development And Commercialization Of MT201
Jun 07, 2010: Micromet Presents Interim Update On Phase I Study Of MT110 In Patients With Advanced Solid Tumors
Dec 06, 2010: Micromet Reports Phase II Study Data Of Blinatumomab In Acute Lymphoblastic Leukemia
Dec 06, 2010: Micromet Reports Phase II Study Data Of Blinatumomab In Acute Lymphoblastic Leukemia
Dec 05, 2006: Micromet And Serono Amend Collaboration Agreement And Continue Development Of Adecatumumab
Apr 05, 2011: Micromet Presents Preclinical Data On MT110
Apr 05, 2011: Micromet's BiTE Antibody MT112/BAY 2010112 Demonstrates Potent Activity Against Human Prostate Cancer Cells
Nov 04, 2008: Micromet Presents The Preclinical Data Of MT201
Oct 04, 2005: Serono Stops Second Phase lll Trial Of Canvaxin In Melanoma
Jun 04, 2007: Micromet Presents Phase II Final Data For Adecatumumab
Aug 03, 2009: Micromet Receives European Orphan Drug Designation For BiTE Antibody Blinatumomab
Feb 02, 2005: Micromet Reports Preclinical Results Of MT201 For Breast Cancer
Jun 01, 2009: Micromet Presents Update At ASCO 2009 On A Phase 1b Combination Study Of Adecatumumab And Docetaxel
Jun 01, 2009: Micromet Presents Update On Phase 1b Combination Study Of Adecatumumab
Financial Deals Landscape
Micromet, Inc., Deals Volume Summary, 2004 to YTD 2011
Micromet, Inc., Deals Summary By Region, 2004 to YTD 2011
Micromet, Inc., Deals Summary, 2004 to YTD 2011
Micromet, Inc. Detailed Deal Summary
Private Equity
Micromet Announces Financing Of $75 Million From Kingsbridge Capital Advisors
Equity Offering
Micromet Completes Public Offering Of $80 Million
Micromet Completes Private Placement Of $25.4 Million
Micromet Completes Private Placement Of $8 Million
Bayer Schering Enters Into Co-Development Agreement With Micromet
Micromet Terminates Co-Development Agreement With MedImmune
Micromet Enters Into An Agreement With Nycomed International Management
Micromet Amends Its Agreement With Serono
Licensing Agreements
Micromet Enters Into Licensing Agreement With Sanofi-Aventis
Micromet Enters Into License Agreement Agreement With TRACON Pharmaceuticals
Micromet Enters Into An Agreement With Morphotek
Micromet Enters Into Licensing Agreement With Serono
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Micromet, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Micromet, Inc. – Pipeline by Stage of Development, H2 2011
Micromet, Inc. – Monotherapy Products in Pipeline, H2 2011
Micromet, Inc. - Pipeline By Target, H2 2011
Micromet, Inc. – Pipeline By Molecule Type, H2 2011
Micromet, Inc. – Recent Pipeline Updates, H2 2011
Micromet, Inc. - Discontinued Pipeline Products, 2010
Micromet, Inc., Subsidiaries
Micromet, Inc., Deals Summary, 2004 to YTD 2011
Micromet, Inc., Deals Summary by Region, 2004 to YTD 2011
Micromet, Inc., Deals Summary, 2004 to YTD 2011

List of Figures
Micromet, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Micromet, Inc. – Pipeline by Stage of Development, H2 2011
Micromet, Inc. – Monotherapy Products in Pipeline, H2 2011
Micromet, Inc. – Pipeline By Molecule Type, H2 2011

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos